Idalopirdine in Patients With Mild-moderate Alzheimer's Disease Treated With Donepezil

The study consisted of a screening period (up to 2-week period from screening to
randomization), a 24-week double-blind treatment period with placebo or idalopirdine 10
mg/day or 30 mg/day as adjunctive therapy to donepezil 10 mg/day, and a 4-week safety
follow-up period following study completion or withdrawal from treatment.

Inclusion Criteria:

- The patient has a knowledgeable and reliable caregiver.

- The patient is an outpatient.

- The patient has probable AD.

- The patient has mild to moderate AD.

- Stable treatment with donepezil.

- The patient, if a woman, must have had her last natural menstruation ≥24 months prior
to baseline, OR be surgically sterile.

- The patient, if a man, agrees to protocol-defined use of effective contraception if
his female partner is of childbearing potential, OR must have been surgically
sterilised prior to the screening visit.

Exclusion Criteria:

- The patient has evidence of any clinically significant neurodegenerative disease, or
other serious neurological disorders other than AD.

- The patient has a Diagnostic and Statistical Manual of Mental Disorders, 4th edition,
Text Revision (DSM-IV-TR) Axis I disorder other than AD.

- The patient has evidence of clinically significant disease.

- The patient's donepezil therapy is likely to be interrupted or discontinued during the
study.

- The patient is currently receiving memantine or has taken memantine within 2 months
prior to screening.

Other inclusion and exclusion criteria may apply.